Servier

This expanded access program offers vorasidenib, an oral drug, to people aged 12 and older with IDH-mutated glioma who have had surgery. The drug targets specific genetic mutations in tumor cells. The goal is to see if it can help control the disease without immediate need for ra…

This study tests an experimental pill, vorasidenib, in Asian patients with a slow-growing but serious brain tumor (grade 2 glioma) that has a specific genetic mutation (IDH1 or IDH2). About 57 participants will receive either the drug or a placebo to see if it delays tumor progre…

This study tests a daily pill called ivosidenib in 12 Japanese patients with advanced bile duct cancer that has an IDH1 mutation and has already been treated with other therapies. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants …